Myasthenia gravis and myasthenic syndrome

Research output: Contribution to journalArticle

Abstract

Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune ion channel disorders mediated by antibodies to postsynaptic acetylcholine receptors and presynaptic voltage-operated calcium channels, respectively. MG and LEMS are currently treated with corticosteroids and immunosuppressive drugs with a positive clinical outcome. Since both diseases are mediated by circulating autoantibodies, they are good candidates for immunomodulation by intravenous immunoglobulins (IVIG). Standardized controlled studies are lacking in this field, but there is general agreement that IVIG are effective. They can be used as an acute treatment to control temporarily the most severe forms of these diseases, as well as a chronic immunomodulating therapy in addition to standard pharmacological treatment. Several aspects of IVIG administration, cost benefit-analysis, and comparison to plasmapheresis are still needed.

Original languageEnglish
JournalNeurological Sciences
Volume24
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Intravenous Immunoglobulins
Myasthenia Gravis
Muscle Weakness
Lambert-Eaton Myasthenic Syndrome
Plasmapheresis
Immunomodulation
Cholinergic Receptors
Calcium Channels
Immunosuppressive Agents
Ion Channels
Intravenous Administration
Autoantibodies
Cost-Benefit Analysis
Adrenal Cortex Hormones
Therapeutics
Pharmacology
Costs and Cost Analysis
Antibodies
Pharmaceutical Preparations

Keywords

  • Immunomodulation
  • Intravenous immunoglobulins
  • Lambert-Eaton myasthenic syndrome
  • Myasthenia gravis
  • Plasmapheresis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Myasthenia gravis and myasthenic syndrome. / Antozzi, C.

In: Neurological Sciences, Vol. 24, No. SUPPL. 4, 10.2003.

Research output: Contribution to journalArticle

@article{621c67d8ccdc4bb99b1c7c064abba84b,
title = "Myasthenia gravis and myasthenic syndrome",
abstract = "Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune ion channel disorders mediated by antibodies to postsynaptic acetylcholine receptors and presynaptic voltage-operated calcium channels, respectively. MG and LEMS are currently treated with corticosteroids and immunosuppressive drugs with a positive clinical outcome. Since both diseases are mediated by circulating autoantibodies, they are good candidates for immunomodulation by intravenous immunoglobulins (IVIG). Standardized controlled studies are lacking in this field, but there is general agreement that IVIG are effective. They can be used as an acute treatment to control temporarily the most severe forms of these diseases, as well as a chronic immunomodulating therapy in addition to standard pharmacological treatment. Several aspects of IVIG administration, cost benefit-analysis, and comparison to plasmapheresis are still needed.",
keywords = "Immunomodulation, Intravenous immunoglobulins, Lambert-Eaton myasthenic syndrome, Myasthenia gravis, Plasmapheresis",
author = "C. Antozzi",
year = "2003",
month = "10",
doi = "10.1007/s10072-003-0091-5",
language = "English",
volume = "24",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Myasthenia gravis and myasthenic syndrome

AU - Antozzi, C.

PY - 2003/10

Y1 - 2003/10

N2 - Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune ion channel disorders mediated by antibodies to postsynaptic acetylcholine receptors and presynaptic voltage-operated calcium channels, respectively. MG and LEMS are currently treated with corticosteroids and immunosuppressive drugs with a positive clinical outcome. Since both diseases are mediated by circulating autoantibodies, they are good candidates for immunomodulation by intravenous immunoglobulins (IVIG). Standardized controlled studies are lacking in this field, but there is general agreement that IVIG are effective. They can be used as an acute treatment to control temporarily the most severe forms of these diseases, as well as a chronic immunomodulating therapy in addition to standard pharmacological treatment. Several aspects of IVIG administration, cost benefit-analysis, and comparison to plasmapheresis are still needed.

AB - Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune ion channel disorders mediated by antibodies to postsynaptic acetylcholine receptors and presynaptic voltage-operated calcium channels, respectively. MG and LEMS are currently treated with corticosteroids and immunosuppressive drugs with a positive clinical outcome. Since both diseases are mediated by circulating autoantibodies, they are good candidates for immunomodulation by intravenous immunoglobulins (IVIG). Standardized controlled studies are lacking in this field, but there is general agreement that IVIG are effective. They can be used as an acute treatment to control temporarily the most severe forms of these diseases, as well as a chronic immunomodulating therapy in addition to standard pharmacological treatment. Several aspects of IVIG administration, cost benefit-analysis, and comparison to plasmapheresis are still needed.

KW - Immunomodulation

KW - Intravenous immunoglobulins

KW - Lambert-Eaton myasthenic syndrome

KW - Myasthenia gravis

KW - Plasmapheresis

UR - http://www.scopus.com/inward/record.url?scp=0142217505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142217505&partnerID=8YFLogxK

U2 - 10.1007/s10072-003-0091-5

DO - 10.1007/s10072-003-0091-5

M3 - Article

C2 - 14598056

AN - SCOPUS:0142217505

VL - 24

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 4

ER -